| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 63 | 2025 | 609 | 19.310 |
Why?
|
| Lung | 35 | 2025 | 1508 | 4.260 |
Why?
|
| Pulmonary Emphysema | 11 | 2025 | 93 | 3.590 |
Why?
|
| Cigarette Smoking | 8 | 2025 | 59 | 3.380 |
Why?
|
| B-Lymphocytes | 7 | 2025 | 534 | 2.740 |
Why?
|
| Asthma | 12 | 2024 | 762 | 2.250 |
Why?
|
| Emphysema | 6 | 2025 | 68 | 2.040 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2024 | 123 | 1.630 |
Why?
|
| Smoking | 10 | 2023 | 1052 | 1.490 |
Why?
|
| Adaptive Immunity | 3 | 2019 | 90 | 1.400 |
Why?
|
| Pneumonia | 5 | 2023 | 328 | 1.240 |
Why?
|
| Smoke | 5 | 2021 | 61 | 1.230 |
Why?
|
| Humans | 86 | 2025 | 126366 | 1.120 |
Why?
|
| MicroRNAs | 3 | 2024 | 868 | 1.040 |
Why?
|
| Tertiary Lymphoid Structures | 2 | 2024 | 5 | 0.880 |
Why?
|
| Respiratory Function Tests | 7 | 2023 | 202 | 0.870 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 30 | 0.860 |
Why?
|
| Bronchitis, Chronic | 1 | 2023 | 18 | 0.850 |
Why?
|
| B-Cell Activating Factor | 2 | 2015 | 4 | 0.840 |
Why?
|
| Achilles Tendon | 1 | 2022 | 10 | 0.800 |
Why?
|
| ADAM Proteins | 3 | 2018 | 82 | 0.800 |
Why?
|
| Disease Progression | 8 | 2023 | 2105 | 0.780 |
Why?
|
| Sexual Behavior | 1 | 2024 | 238 | 0.780 |
Why?
|
| Proteostasis | 1 | 2022 | 36 | 0.740 |
Why?
|
| Pneumonectomy | 1 | 2023 | 148 | 0.740 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2023 | 166 | 0.740 |
Why?
|
| Protective Agents | 1 | 2021 | 35 | 0.730 |
Why?
|
| Inhalation | 1 | 2020 | 8 | 0.700 |
Why?
|
| Forced Expiratory Volume | 6 | 2023 | 173 | 0.700 |
Why?
|
| Inhalation Exposure | 1 | 2020 | 37 | 0.690 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 367 | 0.690 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 381 | 0.690 |
Why?
|
| Spirometry | 4 | 2024 | 73 | 0.690 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2020 | 27 | 0.670 |
Why?
|
| Respiratory Tract Infections | 1 | 2022 | 275 | 0.650 |
Why?
|
| Metformin | 1 | 2021 | 154 | 0.640 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2019 | 44 | 0.630 |
Why?
|
| Airway Remodeling | 5 | 2025 | 21 | 0.630 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 611 | 0.630 |
Why?
|
| Epidemics | 2 | 2024 | 54 | 0.620 |
Why?
|
| Antigens, CD | 2 | 2018 | 432 | 0.610 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 357 | 0.610 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2018 | 30 | 0.590 |
Why?
|
| Middle Aged | 24 | 2025 | 27046 | 0.590 |
Why?
|
| Vital Capacity | 3 | 2023 | 77 | 0.580 |
Why?
|
| Uteroglobin | 4 | 2021 | 46 | 0.570 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 86 | 0.570 |
Why?
|
| Lymphoid Tissue | 2 | 2015 | 48 | 0.570 |
Why?
|
| Mice | 29 | 2025 | 17877 | 0.570 |
Why?
|
| Inflammation | 2 | 2024 | 1463 | 0.560 |
Why?
|
| Postmenopause | 1 | 2018 | 129 | 0.550 |
Why?
|
| Endothelium | 1 | 2017 | 68 | 0.540 |
Why?
|
| Male | 36 | 2025 | 62042 | 0.530 |
Why?
|
| Lung Diseases | 1 | 2020 | 390 | 0.530 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 89 | 0.530 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 4465 | 0.520 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 259 | 0.520 |
Why?
|
| Pandemics | 3 | 2020 | 1129 | 0.520 |
Why?
|
| Proteomics | 4 | 2024 | 514 | 0.510 |
Why?
|
| Aged | 21 | 2025 | 19978 | 0.510 |
Why?
|
| Membrane Proteins | 4 | 2021 | 1558 | 0.510 |
Why?
|
| Female | 38 | 2025 | 67337 | 0.510 |
Why?
|
| Precision Medicine | 1 | 2019 | 325 | 0.500 |
Why?
|
| Bone and Bones | 1 | 2018 | 271 | 0.500 |
Why?
|
| Animals | 32 | 2025 | 34548 | 0.490 |
Why?
|
| Disease Models, Animal | 15 | 2025 | 4468 | 0.470 |
Why?
|
| Hoarseness | 1 | 2013 | 13 | 0.410 |
Why?
|
| Nerve Compression Syndromes | 1 | 2013 | 21 | 0.410 |
Why?
|
| Pulmonary Alveoli | 3 | 2024 | 136 | 0.410 |
Why?
|
| Pharyngitis | 1 | 2013 | 32 | 0.410 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 75 | 0.410 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2013 | 10 | 0.400 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1677 | 0.400 |
Why?
|
| Hypoxia | 1 | 2014 | 256 | 0.390 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2013 | 75 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2023 | 408 | 0.380 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 2934 | 0.370 |
Why?
|
| Pneumonia, Mycoplasma | 2 | 2021 | 13 | 0.370 |
Why?
|
| Kidney | 2 | 2018 | 1361 | 0.360 |
Why?
|
| Respiration | 2 | 2023 | 122 | 0.350 |
Why?
|
| Macrophages, Alveolar | 3 | 2024 | 49 | 0.340 |
Why?
|
| Pulmonary Embolism | 1 | 2013 | 176 | 0.340 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 434 | 0.340 |
Why?
|
| Oxidative Stress | 6 | 2024 | 832 | 0.340 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 54 | 0.330 |
Why?
|
| Mice, Knockout | 12 | 2025 | 3775 | 0.330 |
Why?
|
| Serine Endopeptidases | 2 | 2021 | 184 | 0.330 |
Why?
|
| Bronchoalveolar Lavage Fluid | 5 | 2018 | 151 | 0.330 |
Why?
|
| Atherosclerosis | 1 | 2017 | 918 | 0.330 |
Why?
|
| Plethysmography | 2 | 2020 | 35 | 0.320 |
Why?
|
| Endothelial Cells | 3 | 2023 | 511 | 0.320 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 2021 | 15 | 0.300 |
Why?
|
| Sex Factors | 2 | 2024 | 1293 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3623 | 0.290 |
Why?
|
| Coitus | 1 | 2008 | 20 | 0.290 |
Why?
|
| Betacoronavirus | 3 | 2020 | 294 | 0.290 |
Why?
|
| Bronchodilator Agents | 3 | 2022 | 151 | 0.290 |
Why?
|
| Mycoplasma pneumoniae | 3 | 2023 | 12 | 0.280 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2825 | 0.280 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 877 | 0.270 |
Why?
|
| Global Health | 2 | 2024 | 574 | 0.270 |
Why?
|
| Adult | 14 | 2025 | 29800 | 0.270 |
Why?
|
| Partial Pressure | 2 | 2018 | 29 | 0.260 |
Why?
|
| Young Adult | 5 | 2022 | 9166 | 0.260 |
Why?
|
| Oxygen | 3 | 2018 | 560 | 0.250 |
Why?
|
| Biomarkers | 5 | 2021 | 3154 | 0.250 |
Why?
|
| Case-Control Studies | 5 | 2021 | 3343 | 0.240 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2025 | 31 | 0.240 |
Why?
|
| Vitronectin | 1 | 2025 | 5 | 0.240 |
Why?
|
| Cohort Studies | 6 | 2025 | 4875 | 0.230 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2024 | 29 | 0.230 |
Why?
|
| Vaping | 1 | 2025 | 30 | 0.230 |
Why?
|
| Americas | 1 | 2024 | 50 | 0.230 |
Why?
|
| Prospective Studies | 4 | 2019 | 6177 | 0.230 |
Why?
|
| Latin America | 1 | 2024 | 93 | 0.230 |
Why?
|
| Lectins, C-Type | 1 | 2024 | 73 | 0.230 |
Why?
|
| Mucus | 1 | 2024 | 37 | 0.220 |
Why?
|
| Comorbidity | 5 | 2022 | 1544 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2018 | 1413 | 0.220 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2024 | 35 | 0.220 |
Why?
|
| Integrin alpha2beta1 | 1 | 2023 | 8 | 0.220 |
Why?
|
| Exhalation | 1 | 2023 | 10 | 0.220 |
Why?
|
| Canada | 1 | 2024 | 291 | 0.220 |
Why?
|
| Respiratory Mucosa | 2 | 2021 | 93 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6652 | 0.220 |
Why?
|
| Respiratory Tract Diseases | 1 | 2024 | 77 | 0.220 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2018 | 92 | 0.210 |
Why?
|
| Th2 Cells | 1 | 2024 | 186 | 0.210 |
Why?
|
| Cullin Proteins | 1 | 2023 | 15 | 0.210 |
Why?
|
| Sarcoidosis | 1 | 2023 | 61 | 0.200 |
Why?
|
| GTPase-Activating Proteins | 1 | 2023 | 89 | 0.200 |
Why?
|
| Enterovirus Infections | 1 | 2023 | 49 | 0.200 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 1789 | 0.200 |
Why?
|
| Menopause | 1 | 2022 | 75 | 0.200 |
Why?
|
| Immunity | 1 | 2023 | 194 | 0.190 |
Why?
|
| Macrophages | 2 | 2024 | 642 | 0.190 |
Why?
|
| Epithelial Cells | 5 | 2021 | 913 | 0.190 |
Why?
|
| Diagnostic Imaging | 1 | 2024 | 280 | 0.190 |
Why?
|
| Bronchiectasis | 1 | 2022 | 21 | 0.190 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 122 | 0.190 |
Why?
|
| Risk Factors | 4 | 2022 | 10377 | 0.190 |
Why?
|
| Friends | 1 | 2021 | 14 | 0.190 |
Why?
|
| Patient Acuity | 1 | 2021 | 67 | 0.180 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 74 | 0.180 |
Why?
|
| Spain | 2 | 2018 | 60 | 0.180 |
Why?
|
| Integrin alpha4beta1 | 1 | 2021 | 37 | 0.180 |
Why?
|
| Bronchi | 1 | 2021 | 102 | 0.180 |
Why?
|
| Tidal Volume | 1 | 2020 | 41 | 0.170 |
Why?
|
| NF-kappa B | 3 | 2023 | 469 | 0.170 |
Why?
|
| Lipids | 1 | 2024 | 524 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2024 | 710 | 0.170 |
Why?
|
| Chromatin | 1 | 2024 | 577 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 495 | 0.170 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2020 | 16 | 0.170 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2021 | 161 | 0.170 |
Why?
|
| Interleukin-13 | 1 | 2020 | 97 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 145 | 0.160 |
Why?
|
| Exercise Tolerance | 2 | 2010 | 84 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 3203 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2020 | 185 | 0.160 |
Why?
|
| Opioid Peptides | 1 | 2018 | 4 | 0.150 |
Why?
|
| Beclin-1 | 1 | 2018 | 26 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 414 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 296 | 0.150 |
Why?
|
| Smokers | 1 | 2018 | 40 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 442 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2020 | 316 | 0.150 |
Why?
|
| Gene Expression | 1 | 2023 | 1563 | 0.150 |
Why?
|
| Ubiquinone | 1 | 2018 | 25 | 0.150 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2023 | 399 | 0.150 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2018 | 59 | 0.150 |
Why?
|
| Creatine | 1 | 2018 | 41 | 0.150 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 208 | 0.150 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 440 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 140 | 0.150 |
Why?
|
| Respiratory Mechanics | 2 | 2018 | 75 | 0.140 |
Why?
|
| Virus Replication | 1 | 2021 | 613 | 0.140 |
Why?
|
| Angiotensins | 1 | 2017 | 8 | 0.140 |
Why?
|
| Bone Development | 1 | 2018 | 58 | 0.140 |
Why?
|
| Tomography | 1 | 2017 | 40 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 134 | 0.140 |
Why?
|
| Vasodilator Agents | 1 | 2018 | 203 | 0.140 |
Why?
|
| Age of Onset | 1 | 2018 | 609 | 0.140 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2020 | 208 | 0.130 |
Why?
|
| Carbon Dioxide | 1 | 2018 | 280 | 0.130 |
Why?
|
| Apoptosis | 4 | 2018 | 1843 | 0.130 |
Why?
|
| Child | 4 | 2022 | 24739 | 0.130 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 129 | 0.130 |
Why?
|
| United States | 2 | 2024 | 10994 | 0.130 |
Why?
|
| Iron Chelating Agents | 1 | 2016 | 15 | 0.130 |
Why?
|
| Bronchitis | 1 | 2016 | 34 | 0.130 |
Why?
|
| Iron-Binding Proteins | 1 | 2016 | 33 | 0.130 |
Why?
|
| Metabolomics | 1 | 2019 | 427 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2021 | 1031 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 323 | 0.120 |
Why?
|
| Antioxidants | 1 | 2018 | 361 | 0.120 |
Why?
|
| Bone Density | 1 | 2018 | 324 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 207 | 0.120 |
Why?
|
| Adolescent | 3 | 2020 | 19531 | 0.120 |
Why?
|
| Ethanolamines | 2 | 2012 | 31 | 0.120 |
Why?
|
| Autoimmunity | 1 | 2016 | 173 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 530 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2022 | 810 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2016 | 176 | 0.120 |
Why?
|
| beta Catenin | 1 | 2016 | 216 | 0.120 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 87 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2012 | 980 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2018 | 474 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 2074 | 0.110 |
Why?
|
| Mitochondria | 2 | 2018 | 696 | 0.110 |
Why?
|
| Follicular Phase | 1 | 2014 | 15 | 0.110 |
Why?
|
| Luteal Phase | 1 | 2014 | 8 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2019 | 771 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1276 | 0.110 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 9 | 0.110 |
Why?
|
| Electron Transport Complex IV | 2 | 2016 | 40 | 0.110 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 3458 | 0.110 |
Why?
|
| Cytokines | 2 | 2018 | 1304 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12386 | 0.110 |
Why?
|
| Phenotype | 2 | 2024 | 4322 | 0.110 |
Why?
|
| Cyclic AMP | 1 | 2014 | 247 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2014 | 65 | 0.110 |
Why?
|
| Posture | 1 | 2014 | 149 | 0.110 |
Why?
|
| Proteolysis | 1 | 2014 | 172 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 378 | 0.100 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2013 | 38 | 0.100 |
Why?
|
| Iron | 1 | 2016 | 281 | 0.100 |
Why?
|
| Time Factors | 2 | 2020 | 6338 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 241 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2022 | 14207 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2010 | 240 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 300 | 0.100 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2012 | 63 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5202 | 0.100 |
Why?
|
| Polysomnography | 1 | 2013 | 146 | 0.100 |
Why?
|
| Neutrophils | 1 | 2014 | 383 | 0.090 |
Why?
|
| Abortion, Spontaneous | 1 | 2013 | 80 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2013 | 364 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 649 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1713 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 1208 | 0.090 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2010 | 1 | 0.090 |
Why?
|
| Lymphocyte Subsets | 1 | 2010 | 38 | 0.090 |
Why?
|
| Mitochondria, Muscle | 1 | 2009 | 35 | 0.080 |
Why?
|
| Hospitalization | 1 | 2018 | 1801 | 0.080 |
Why?
|
| Prognosis | 1 | 2019 | 4734 | 0.080 |
Why?
|
| Collagen | 2 | 2025 | 319 | 0.080 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 108 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2023 | 510 | 0.080 |
Why?
|
| Body Weight | 1 | 2013 | 1004 | 0.080 |
Why?
|
| Testosterone | 1 | 2014 | 559 | 0.080 |
Why?
|
| Uterus | 1 | 2013 | 568 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 829 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1582 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2406 | 0.060 |
Why?
|
| Walking | 1 | 2008 | 218 | 0.060 |
Why?
|
| Lung Injury | 2 | 2018 | 122 | 0.060 |
Why?
|
| Prevalence | 2 | 2022 | 2484 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2025 | 4640 | 0.060 |
Why?
|
| Leukocytes | 2 | 2018 | 213 | 0.060 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2025 | 50 | 0.060 |
Why?
|
| Heart Rate | 1 | 2008 | 583 | 0.060 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2025 | 14 | 0.060 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2025 | 39 | 0.060 |
Why?
|
| Exercise | 1 | 2010 | 828 | 0.060 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2023 | 8 | 0.050 |
Why?
|
| Tryptases | 1 | 2023 | 20 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 1006 | 0.050 |
Why?
|
| Poly I-C | 1 | 2023 | 23 | 0.050 |
Why?
|
| Phenyl Ethers | 1 | 2023 | 9 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2024 | 163 | 0.050 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 62 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2023 | 62 | 0.050 |
Why?
|
| Rhinovirus | 1 | 2023 | 59 | 0.050 |
Why?
|
| Ovalbumin | 1 | 2023 | 319 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 170 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 510 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 260 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 356 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 502 | 0.050 |
Why?
|
| Vascular Remodeling | 1 | 2021 | 42 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2024 | 435 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2276 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 362 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2024 | 674 | 0.050 |
Why?
|
| Formoterol Fumarate | 2 | 2012 | 31 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2021 | 64 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2021 | 68 | 0.040 |
Why?
|
| Dyspnea | 1 | 2022 | 156 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 154 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 564 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2023 | 416 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 387 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2025 | 888 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2021 | 348 | 0.040 |
Why?
|
| Pregnancy | 1 | 2013 | 7258 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 259 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 876 | 0.040 |
Why?
|
| Receptors, Opioid | 1 | 2018 | 14 | 0.040 |
Why?
|
| Exercise Test | 2 | 2010 | 256 | 0.040 |
Why?
|
| Lung Compliance | 1 | 2018 | 19 | 0.040 |
Why?
|
| Airway Resistance | 1 | 2018 | 36 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 25 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 1261 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2018 | 109 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2018 | 135 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 251 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 114 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 1762 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2018 | 179 | 0.030 |
Why?
|
| Transcriptome | 1 | 2023 | 1013 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 447 | 0.030 |
Why?
|
| Iron Regulatory Protein 2 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Mucociliary Clearance | 1 | 2016 | 4 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1725 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 834 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2016 | 49 | 0.030 |
Why?
|
| Iron, Dietary | 1 | 2016 | 16 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 401 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 164 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 48 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 474 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 127 | 0.030 |
Why?
|
| Body Composition | 1 | 2018 | 532 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 199 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 309 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2015 | 2 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2015 | 19 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 402 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2015 | 24 | 0.030 |
Why?
|
| Rats | 1 | 2021 | 3764 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 491 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 135 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 156 | 0.030 |
Why?
|
| Blood-Air Barrier | 1 | 2014 | 4 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2014 | 8 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 1 | 2014 | 14 | 0.030 |
Why?
|
| Methacholine Chloride | 1 | 2014 | 21 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 123 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 329 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 353 | 0.030 |
Why?
|
| Elastin | 1 | 2014 | 31 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1613 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2071 | 0.030 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2014 | 66 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2014 | 30 | 0.030 |
Why?
|
| Prolactin | 1 | 2014 | 113 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 2014 | 131 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 135 | 0.030 |
Why?
|
| Bleomycin | 1 | 2014 | 153 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2195 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2399 | 0.030 |
Why?
|
| Sputum | 1 | 2014 | 106 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2014 | 187 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2108 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 130 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 806 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2738 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 38 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 302 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 424 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2018 | 666 | 0.020 |
Why?
|
| Eosinophils | 1 | 2013 | 120 | 0.020 |
Why?
|
| Estradiol | 1 | 2014 | 528 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 449 | 0.020 |
Why?
|
| Progesterone | 1 | 2014 | 621 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 217 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3166 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8301 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 684 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 1304 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2010 | 183 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 435 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 306 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 807 | 0.020 |
Why?
|
| Health Status | 1 | 2010 | 385 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12667 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 16522 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 2621 | 0.010 |
Why?
|